Soluble PD-1/PD-L1 biomarkers in NSCLC: prognostic and diagnostic value.
Blood-based biomarkers may help predict immunotherapy response and durability better than tissue testing alone in lung cancer.
BACKGROUND: Tissue-based immunohistochemistry (IHC) for programmed death-ligand 1 (PD-L1) remains the clinical standard for guiding immunotherapy selection in non-small cell lung cancer (NSCLC) but is Circulating sPD-L1 serves as a reliable negative indicator of therapeutic efficacy and surgical durability, whereas on-treatment tracking of sPD-1 captures protective host T-cell clonal reactivation. Results and implications require full-text review.
What the study was
- Study design
- Cross-sectional study
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Mol Cell Probes
Why it surfaced
Score 7/10 meets STANDARD threshold for this cross-sectional study on Early cancer detection, Novel therapeutics: immunotherapy, CAR-T, targeted therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.